Modification of cardiometabolic risk through cannabinoid type-1 receptor antagonism

Angiology

Volumn 59, Issue 2_suppl, 2008, Pages 44S-48S

  Andrikopoulos, George K ^a   Tzeis, Stylianos ^b  

^a Evaggelismos Hospital   (Greece)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

endocannabinoid system; obesity; rimonabant

Indexed keywords

C REACTIVE PROTEIN; CANNABINOID 1 RECEPTOR ANTAGONIST; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; RIMONABANT; CANNABINOID 2 RECEPTOR; PIPERIDINE DERIVATIVE; PYRAZOLE DERIVATIVE;

APPETITE DISORDER; CARDIOMETABOLIC RISK; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CONFERENCE PAPER; DEPRESSION; FOOD INTAKE; GLUCOSE BLOOD LEVEL; HUMAN; MAGNITUDE ESTIMATION METHOD; MEDITERRANEAN DIET; MORTALITY; OBESITY; PERFORMANCE; TRIACYLGLYCEROL BLOOD LEVEL; DRUG ANTAGONISM; METABOLISM; REVIEW; RISK FACTOR;

CARDIOVASCULAR DISEASES; HUMANS; OBESITY; PIPERIDINES; PYRAZOLES; RECEPTOR, CANNABINOID, CB2; RISK FACTORS;

EID: 53049085908     PISSN: 00033197     EISSN: 19401574     Source Type: Journal    
DOI: 10.1177/0003319708320938     Document Type: Conference Paper

References (38)

1. Poirier P., Giles TD, Bray GA, et al. Obesity and cardiovascular disease: pathophysiology, evaluation, and effect of weight loss: an update of the 1997 American Heart Association Scientific Statement on Obesity and Heart Disease from the Obesity Committee of the Council on Nutrition, Physical Activity, and Metabolism. Circulation. 2006; 113: 898-918.
2. Panagiotakos DB, Pitsavos C., Chrysohoou C., et al. Epidemiology of overweight and obesity in a Greek adult population: the ATTICA Study. Obes Res. 2004; 12: 1914-1920.
3. Andrikopoulos GK. The Hellenic Heart Foundation. Interview by Robert Short. Circulation. 2007; 116: f129-f131.
4. Hill JO, Peters JC Environmental contributions to the obesity epidemic. Science. 1998; 280: 1371-1374.
5. Lazar MA How obesity causes diabetes: not a tall tale. Science. 2005; 307: 373-375.
6. Zhang C., Rexrode KM, van Dam RM, Li TY, Hu FB Abdominal obesity and the risk of all-cause, cardiovascular, and cancer mortality: sixteen years of follow-up in US women. Circulation. 2008; 117: 1658-1667.
7. Andrikopoulos G., Pipilis A., Goudevenos J., et al. Epidemiological characteristics, management and early outcome of acute myocardial infarction in Greece. The Hellenic Infarction Observation Study. Hellenic J Cardiol. 2007; 48: 325-334.
8. Andrikopoulos GK, Richter DJ, Dilaveris PE, et al. In-hospital mortality of habitual cigarette smokers after acute myocardial infarction; the "smoker's paradox" in a countrywide study. Eur Heart J. 2001; 22: 724-726.
9. Wajchenberg BL Subcutaneous and visceral adipose tissue: their relation to the metabolic syndrome. Endocr Rev. 2000; 21: 697-738.
10. Carr MC, Brunzell JD Abdominal obesity and dyslipidemia in the metabolic syndrome: importance of type 2 diabetes and familial combined hyperlipidemia in coronary artery disease risk. J Clin Endocrinol Metab. 2004; 89: 2601-2607.
11. Haslam DW, James WP Obesity. Lancet. 2005; 366: 1197-1209.
12. Lambert DM, Fowler CJ The endocannabinoid system: drug targets, lead compounds and potential therapeutic applications. J Med Chem. 2005; 48: 5059-5087.
13. Di Marzo D., Bifulco M., De Petrocellis L. The endocannabinoid system and its therapeutic exploitation. Nat Rev Drug Discov. 2004; 3: 771-784.
14. Pagotto U., Vicennati V., Pasquali R. The endocannabinoid system and the treatment of obesity. Ann Med. 2005; 37: 270-275.
15. Engeli S., Böhnke J., Feldpausch M., et al. Activation of the peripheral endocannabinoid system in human obesity. Diabetes. 2005; 54: 2838-2843.
16. Pertwee RG Cannabinoids and the gastrointestinal tract. Gut. 2001; 48: 859-867.
17. Cota D., Marsicano G., Tschöp M., et al. The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis. J Clin Invest. 2003; 112: 423-431.
18. Ravinet-Trillou C., Delgorge C., Menet C., Arnone M., Soubrié P. CB1 cannabinoid receptor knockout in mice leads to leanness, resistance to diet-induced obesity and enhanced leptin sensitivity. Int J Obes Relat Metab Disord. 2004; 28: 640-648.
19. Liu YL, Connoley IP, Wilson CA, Stock MJ Effects of the cannabinoid CB1 receptor antagonist SR141716 on oxygen consumption and soleus muscle glucose uptake in Lep(ob)/Lep(ob) mice. Int J Obes (Lond). 2005; 29: 183-187.
20. Osei-Hyiaman D., DePetrillo M., Pacher P., et al. Endocannabinoid activation at hepatic CB1 receptors stimulates fatty acid synthesis and contributes to diet-induced obesity. J Clin Invest. 2005; 115: 1298-1305.
21. Bensaid M., Gary-Bobo M., Esclangon A., et al. The cannabinoid CB1 receptor antagonist SR141716 increases Acrp30 mRNA expression in adipose tissue of obese fa/fa rats and in cultured adipocyte cells. Mol Pharmacol. 2003; 63: 908-914.
22. Pagotto U., Marsicano G., Cota D., Lutz B., Pasquali R. The emerging role of the endocannabinoid system in endocrine regulation and energy balance. Endocr Rev. 2006; 27: 73-100.
23. Van Gaal LF, Rissanen AM, Scheen AJ, Ziegler O., Rossner S., for the RIO-Europe Study Group. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet. 2005; 365: 1389-1397.
24. Despres JP, Golay A., Sjostrom L., for the Rimonabant in Obesity-Lipids Study Group. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N Engl J Med. 2005; 353: 2121-2134.
25. Pi-Sunyer FX, Aronne LJ, Heshmati HM, Devin J., Rosenstock J., for the RIO-North America Study Group. Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients. JAMA. 2006; 295: 761-775.
26. Scheen AJ, Finer N., Hollander P., Jensen MD, Van Gaal LF, RIO Diabetes Study Group. Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes. Lancet. 2006; 368: 1160-1172.
27. Padwal RS, Majumdar SR Drug treatments for obesity: orlistat, sibutramine, and rimonabant. Lancet. 2007; 369: 71-77.
28. Nissen SE, Nicholls SJ, Wolski K., et al. Effect of rimonabant on progression of atherosclerosis in patients with abdominal obesity and coronary artery disease. The STRADIVARIUS randomized controlled trial. JAMA. 2008; 299: 1547-1560.
29. Christensen R., Kristensen PK, Bartels EM, Bliddal H., Astrup A. Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials. Lancet. 2007; 370: 1706-1713.
30. Barry D., Pietrzak RH, Petry NM Gender differences in associations between body mass index and DSM-IV mood and anxiety disorders: results from the National Epidemiologic Survey on Alcohol and Related Conditions. Ann Epidemiol. 2008; 18: 458-466.
31. Petry NM, Barry D., Pietrzak RH, Wagner JA Overweight and obesity are associated with psychiatric disorders: results from the National Epidemiologic Survey on Alcohol and Related Conditions. Psychosom Med. 2008; 70: 288-297.
32. Pickering RP, Grant BF, Chou SP, Compton WM Are overweight, obesity, and extreme obesity associated with psychopathology? Results from the National Epidemiologic Survey on Alcohol and Related Conditions. J Clin Psychiatry. 2007; 68: 998-1009.
33. Simon GE, Von Korff M., Saunders K., et al. Association between obesity and psychiatric disorders in the US adult population. Arch Gen Psychiatry. 2006; 63: 824-830.
34. Gantz I., et al. A two-year study to assess the efficacy, safety and tolerability of taranabant in obese patients: 52 week results. Paper presented at: 57th Annual Meeting of the American College of Cardiology, ACC 2008; Abstract 1021-220. http://www.medpagetoday.com/MeetingCoverage/ACCMeeting/tb/8971.
35. Mitchell PB, Morris MJ Depression and anxiety with rimonabant. Lancet. 2007; 370: 1671-1672.
36. Barter PJ, Caulfield M., Eriksson M., et al. ILLUMINATE investigators. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med. 2007; 357: 2109-2122.
37. Kastelein JJ, Akdim F., Stroes ES, et al. ENHANCE investigators. Simvastatin with or without ezetimibe in familial hypercholesterolemia. N Engl J Med. 2008; 358: 1431-1443.
38. Goff DC Jr, Gerstein HC, Ginsberg HN, et al. ACCORD Study Group. Prevention of cardiovascular disease in persons with type 2 diabetes mellitus: current knowledge and rationale for the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Am J Cardiol. 2007; 99: 4i-20i.